Comparative Pharmacology
Head-to-head clinical analysis: PRISMASOL BK 0 0 IN PLASTIC CONTAINER versus PRISMASOL BK 0 0 1 2 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRISMASOL BK 0 0 IN PLASTIC CONTAINER versus PRISMASOL BK 0 0 1 2 IN PLASTIC CONTAINER.
PRISMASOL BK 0/0 IN PLASTIC CONTAINER vs PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Prismasol BK 0/0 is a sterile, nonpyrogenic bicarbonate-buffered replacement solution for continuous renal replacement therapy (CRRT). It acts as an electrolyte and buffer replacement to correct acid-base disturbances and maintain fluid balance during hemofiltration, with no pharmacologic active drug component.
Prismasol BK 0/0/1.2 is a sterile, nonpyrogenic, bicarbonate-buffered solution used for continuous renal replacement therapy (CRRT). It provides electrolyte composition to maintain acid-base balance and electrolyte homeostasis during hemofiltration or hemodialysis. Its mechanism involves correction of metabolic acidosis via bicarbonate buffer, and removal of uremic toxins through convective and/or diffusive clearance.
Replacement solution for continuous renal replacement therapy (CRRT) in patients with acute kidney injury (AKI) or fluid overloadCorrection of metabolic acidosis and electrolyte imbalances during CRRT
FDA-approved: Continuous renal replacement therapy (CRRT) for patients with acute renal failure (ARF) or acute kidney injury (AKI) requiring hemofiltration or hemodialysis.Off-label: Not typically applicable; used specifically for CRRT under medical supervision.
Administered as a continuous infusion at rates typically between 1000-4000 mL/hour depending on the desired effluent flow rate, patient fluid balance, and metabolic requirements. The solution is used as dialysate (hemodiafiltration) or replacement fluid (hemofiltration). Must be prescribed and administered under physician supervision using intravenous infusion via a dialyzer or hemofilter.
Continuous renal replacement therapy (CRRT): 1.2 mmol/L potassium dialysate/ replacement fluid, infused at a rate of 2000-3000 mL/hour, adjusted to achieve desired electrolyte balance and fluid removal.
None Documented
None Documented
Not applicable; PRISMASOL is a dialysate solution, not a drug with systemic absorption; components are removed by dialysis.
Not applicable as a drug; the half-life of bicarbonate in CRRT depends on the dialysis dose and patient's metabolic rate. Typical half-life of infused bicarbonate is minutes due to rapid equilibration. The electrolytes are continuously removed during therapy.
Not metabolized; components are directly exchanged during the CRRT process and eliminated renally or via the filter.
Not metabolized; components undergo renal replacement clearance via CRRT circuit.
Renal (80-100% in urine as unabsorbed, not metabolized); minimal biliary/fecal.
PRISMASOL BK 0/0/1.2 is a bicarbonate-based substitution fluid used in continuous renal replacement therapy (CRRT). It is not absorbed systemically; its components are eliminated according to their individual pharmacokinetics during CRRT. Bicarbonate is primarily eliminated via the dialysate/effluent (renal replacement route). Calcium and magnesium are also removed via CRRT. Less than 1% is excreted in feces or bile.
Not applicable; electrolytes and buffer components are not protein-bound.
Negligible; bicarbonate, calcium, and magnesium are free ions with essentially no protein binding (<1%).
Not applicable; distribution is confined to the extracorporeal circuit and dialyzer; solutes distribute according to body water compartments.
Electrolytes distribute into extracellular fluid (approximately 0.2 L/kg for bicarbonate, calcium, and magnesium). This reflects the volume of the extracellular space.
Intravenous via dialyzer; bioavailability is 100% for delivered components.
Intravenous (via CRRT circuit): 100% bioavailable, as the solution is directly infused into the bloodstream.
No dose adjustment required; intended for use in patients with acute renal failure. The rate of administration is titrated to achieve desired clearance and fluid balance, not based on GFR.
Not applicable. This drug is used specifically for renal replacement therapy in patients with acute kidney injury or end-stage renal disease. Dosing is based on CRRT prescription.
Data not established; no specific hepatic adjustment is required as the solution does not rely on hepatic metabolism. In patients with hepatic encephalopathy, careful monitoring of fluid balance is recommended.
No specific hepatic adjustment required. Drug is a dialysate/replacement fluid for CRRT; its components are not hepatically metabolized.
Safety and efficacy in pediatric patients have not been established. Use is at the discretion of the physician and typically adjusted based on weight and clinical status; no standardized pediatric dosing exists.
CRRT in pediatric patients: Dose (flow rate) based on body weight, typically 2000-3000 mL/1.73 m²/hour, adjusted to target electrolyte and fluid balance. Consult pediatric nephrology.
No specific geriatric dose adjustment required. Caution in elderly patients with compromised cardiovascular function due to risk of volume overload; monitor fluid balance and electrolytes closely.
No specific geriatric adjustment. Use standard CRRT protocols with careful monitoring of fluid balance and electrolytes due to age-related changes in renal and cardiovascular function.
Not for intravenous administration without the use of a CRRT machine. Must be used only with appropriate medical supervision.
None. No FDA-mandated black box warnings.
["Monitor serum electrolytes, acid-base status, and fluid balance closely during CRRT","Risk of electrolyte imbalances (e.g., hyperkalemia, hypophosphatemia) if solution composition is not adjusted for patient needs","Use with caution in patients with severe hepatic failure or lactic acidosis as bicarbonate may not correct acidosis adequately","Ensure proper vascular access and CRRT circuit function"]
["Electrolyte disturbances: Monitor serum electrolytes, acid-base status, and fluid balance frequently.","Hyperkalemia risk: Contains potassium at low concentration (0 mEq/L in this formulation), but patients may require adjustment.","Extravasation: Avoid extravasation; monitor catheter site.","Use only by trained personnel in appropriate clinical setting."]
["Hypersensitivity to any component of the solution","Patients with severe metabolic alkalosis","Concomitant administration of medications incompatible with bicarbonate or calcium-containing solutions"]
["Hypersensitivity to any component","Severe hypokalemia (as solution contains no potassium; may exacerbate)","Severe hypernatremia or metabolic alkalosis (use caution)","Incorrect formulation for patient's electrolyte needs"]
Data Pending Review
Data Pending Review
No specific food interactions with the solution itself; however, dietary potassium and bicarbonate precursors should be restricted per clinical status. Avoid high-potassium foods (bananas, oranges, potatoes) during therapy. Enteral nutrition formulations may require adjustment.
No direct food interactions as the solution is administered intravenously via CRRT. However, dietary potassium and phosphate restrictions may be required based on serum electrolyte levels.
PRISMASOL BK 0/0 is a sterile, nonpyrogenic solution for hemofiltration/hemodiafiltration containing only electrolytes and buffer (bicarbonate). No teratogenic effects in animal studies; human data limited. No known risk of structural anomalies based on its composition. However, use in pregnancy only if clearly needed, as the underlying renal condition may pose risks.
PRISMASOL BK 0/0/1.2 is a bicarbonate-based hemofiltration solution. No human or animal data exist on teratogenicity; however, electrolyte and acid-base disturbances from maternal use could theoretically affect fetal development. No known direct teratogenic risk from the solution components at therapeutic levels.
Excretion into breast milk unknown. Based on composition (electrolytes and bicarbonate), minimal systemic absorption unlikely to affect infant. No M/P ratio available. Use with caution, weighing benefits of maternal treatment against potential risks.
No data on excretion into breast milk. PRISMASOL components are endogenous substances (electrolytes, bicarbonate); systemic levels after regional citrate anticoagulation are expected to be low. M/P ratio unknown. Benefit of maternal treatment should outweigh potential risk to nursing infant.
No pharmacokinetic studies in pregnancy. Due to increased plasma volume and GFR, electrolyte requirements may alter, but dose adjustments not typically required as solution is tailored to individual needs. Monitor electrolytes and adjust composition if needed; bicarbonate buffer may need titration based on acid-base status.
No specific dose adjustments for PRISMASOL in pregnancy; however, careful monitoring and adjustment of flow rates and citrate infusion may be needed due to pregnancy-induced hemodynamic and metabolic changes (e.g., increased glomerular filtration rate, volume expansion).
Category C
Category C
PRISMASOL BK 0/0 is a custom hemodiafiltration solution with zero potassium and zero bicarbonate, designed for continuous renal replacement therapy (CRRT) in patients with severe hyperkalemia or metabolic alkalosis. Monitor serum electrolytes, acid-base status, and fluid balance closely. Do not use for intravenous infusion; only for extracorporeal circulation. Verify compatibility with anticoagulation (e.g., citrate) to avoid hypocalcemia.
PRISMASOL BK 0/0/1.2 is a bicarbonate-based hemofiltration solution for continuous renal replacement therapy (CRRT). It contains zero potassium, zero phosphate, and 1.2 mmol/L magnesium. Use in patients with hyperkalemia or renal failure requiring potassium restriction. Monitor electrolytes closely; avoid in patients with hypokalemia. The solution provides bicarbonate buffer, reducing acidemia in AKI.
This solution is used only during CRRT; not a direct infusion.You will have frequent blood tests to monitor potassium and acid-base levels.Report symptoms of tingling, muscle cramps, or irregular heartbeat.Dietary modifications may be needed based on electrolyte levels.This treatment does not replace dietary potassium restriction.
This solution is only used during dialysis and is not a direct medication you take.Your dialysis machine will use this fluid to help clean your blood and maintain electrolyte balance.Your healthcare team will monitor your blood levels closely during treatment.Do not attempt to warm or alter the solution in any way.